Placement

PROCEDURE2 trials

Sponsors

Light Sciences Oncology, Mayo Clinic

Conditions

Benign Prostatic HyperplasiaDiffuse GliomaLower Urinary Tract SymptomsMalignant Glioma

Early Phase 1

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

RecruitingNCT05717153

Mayo ClinicDiffuse Glioma, Malignant Glioma

Start: 2023-10-01End: 2027-09-15Target: 18Updated: 2025-11-04

Phase 2

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

CompletedNCT00918034

Light Sciences OncologyBenign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Start: 2009-05-31End: 2011-02-28Updated: 2012-11-16

Related Papers

A first-in-human pharmacodynamic evaluation of dual polyamine depletion for patients with high-grade gliomas.

Journal of Clinical Oncology2023-06-011 citations